Constitutive Atg5 overexpression in mouse bone marrow endothelial progenitor cells improves experimental acute kidney injury
Abstract

Background

Endothelial Progenitor Cells have been shown as effective tool in experimental AKI. Several pharmacological strategies for improving EPC-mediated AKI protection were identified in recent years. Aim of the current study was to analyze consequences of constitutive Atg5 activation in murine EPCs, utilized for AKI therapy.

Methods

Ischemic AKI was induced in male C57/Bl6N mice. Cultured murine EPCs were systemically injected post-ischemia, either natively or after Atg5 transfection (Adenovirus-based approach). Mice were analyzed 48 hours and 6 weeks later.

Results

Both, native and transfected EPCs (EPCsAtg5) improved persisting kidney dysfunction at week 6, such effects were more pronounced after injecting EPCsAtg5. While matrix deposition and mesenchymal transdifferentiation of endothelial cells remained unaffected by cell therapy, EPCs, particularly EPCsAtg5 completely prevented the post-ischemic loss of peritubular capillaries. The cells finally augmented the augophagocytic flux in endothelial cells.

Conclusions

Constitutive Atg5 activation augments AKI-protective effects of murine EPCs. The exact clinical consequences need to be determined.

Background

Syngeneic Proangiogenic Cells (PACs) have been proven as an effective tool in experimental AKI [1-5]. The cells, which in previous years were defined as early Endothelial Progenitor Cells (eEPCs or simply EPCs as opposed to Endothelial Colony Forming Cells – ECFCs; for further references see [6, 7]), have repeatedly been applied in murine AKI, therapeutic effects were robust [1-5]. Own studies performed in the past focused on pharmacological strategies suitable for improving PAC (EPC) mediated AKI protection. Numerous substances with agonistic potency were identified [3, 4, 8-10]. Two of our studies addressed the hypothesis that autophagy activation in PACs can increase renoprotective
effects of the cells. The term autophagy (AP) describes a process of intracellular protein degradation, it happens under physiological and non-physiological conditions. Certain stimuli, such as substrate deprivation, can augment AP and thus potentially prolong the lifespan of cells [11]. The so-called autophagocytic cascade involves the proteolytic activation of numerous proteins, the Atgs (Autophagy-related proteins) [12]. Meanwhile more than 30 members of the Atg family have been identified. We do not intend to review the highly complex cascade of AP initiation now. However, in the past we attempted to activate AP in syngeneic PACs by pharmacological measures. In one study, the mediators SuberoylAnilide Hydroxamic Acid (SAHA) and Temsirolimus were employed [13], the second study involved the use of MG-132 (proteasome inhibitor) and of zVAD (pan-caspase inhibitor) [14], respectively. Both studies, of which the second one was performed in diabetic mice, failed to show sustained beneficial effects of pharmacological preconditioning. The reasons for these findings are speculative in nature. One potential explanation is a lack of specificity, the drugs which were applied may have activated pathways not exclusively involved in AP. We therefore aimed to stimulate AP in a more specific manner. In the current study we selectively overexpressed the protein Atg5 in murine PACs, the latter were subsequently injected in post-ischemic mice. Regarding the highly complex dynamics of Atg interactions, one may ask why we decided to exclusively target the protein Atg5. The in vitro deletion of Atg5 has been reported to diminish the endothelial release of the von Willebrand factor [15]. In addition Atg5 inhibition has been shown to reduce the competence of rat EPCs [16]. Finally, a lack of the protein has been documented to aggravate vascular pathology in experimental diabetic nephropathy [17]. Together, these findings clearly suggest a pro-endothelial role of Atg5.

Since we employed a commercially available cell line in our study, the cells will termed EPCs throughout the article.

Methods
Atg5 transfection of murine EPCs
Murine EPCs (C57Bl/6 mouse bone marrow progenitor endothelial Cells; Cellbiologics®, C57-6031) were cultured according to the manufacturer´s protocol. In general, cell transduction was performed
using the ViraDuctin™ Adenovirus Transduction Reagent (Cell Biolabs®). Thus, the procedure was performed according to the manufacturer’s instructions. One day before transduction, cells were trypsinized and counted. Subsequently, $2 \times 10^5$ cells were suspended in 2–3 mL of medium (6-well plate) and incubated at 37 °C overnight. At the day of the transduction, we followed the protocol as mentioned. After finishing the procedure, $1 \times 10^6$ cells were concentrated in 100 µL of medium (M1168, Cell Biologics®), respectively, and used for systemic administration in post-ischemic animals. One transduction series allowed to harvest cells for a total number of 10 mice. At the end of every transduction series, a representative number of cells was investigated for red fluorescence in order to confirm Atg5 expression.

**Animal model and surgery**

As usual in all of our previous animal-based studies, all protocols were performed according to the guidelines of the German Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of Göttingen. As in previous mouse studies, we employed male C57/Bl6N mice (8–12 weeks old). Animals were bred in the local animal facility of the Göttingen University Hospital. Mice were separately caged with a 12:12-h light-dark cycle and had free access to water and chow throughout the study. For anesthesia, the following components were administered intraperitoneally: 300µL 6 mg/100 g ketamine hydrochloride plus 0.77 mg/100 g of xylazine hydrochloride. Animals were subsequently placed on a heated surgical pad and kept there during the whole procedure. Rectal temperature was maintained at 37 °C throughout. The abdomen was opened (1.5-cm midlaparotomy) and both renal pedicles were clamped using microserrefines (Fine Science Tools, Forster City, USA) for 40 minutes, respectively. After releasing the clamps, a constant volume (100 µl) of PAC-containing Endothelial Growth Basal Medium-2 (EBM-2 - Clonetics, Lonza, Walkersville, MD, USA) was injected into the systemic circulation via the tail vein. The respective cell number per injection was $1 \times 10^6$. The abdominal incision was closed with a 4 − 0 suture and surgical staples. In each experimental group 10 animals were analyzed. Animals were sacrificed at 48 hours and 6 weeks respectively. Euthanization was performed by injecting the threefold dose of anaesthesia, followed by dissecting the diaphragm.
Serum cystatin C
Serum Cystatin C was quantified using a commercially available kit (BioVendor, RD291009200R) according to the manufacturer’s instructions.

Proteinuria
For measuring proteinuria, animals were held in metabolic cages for 12 hours, urine was collected over the whole period. Twenty mL of urine were mixed with 980µL of Bradford reagent and incubated at room temperature for 10 minutes. Subsequently, probes were measured at a wave length of 595 nm. Proteinuria was calculated by mg per mL urine/day and finally given as mg/day.

Masson trichrome staining
Masson trichrome staining was performed as in several studies published previously [13, 14, 18].

Immunofluorescence analyses
The methods used for immunofluorescence staining have been published previously [19]. However, the essential steps shall be outlined briefly. In general, EndoMT was evaluated in sections stained for CD31 and alpha-Smooth Muscle Actin (aSMA), the endothelial expression of p62 was quantified after co-staining of CD31 and p62. The peritubular capillary density (PTCD) was analyzed in sections stained for CD31 alone. Formalin fixated, paraffin-embedded tissue sections were deparaffinized, followed by incubation in 3% H2O2 for 10 minutes. Subsequently, sections were treated with citrate buffer for 3 minutes (5 times), followed by blocking with 5% goat serum for 30 minutes (room temperature). Primary incubation was performed with rat anti-mouse CD31 (PECAM-1 - CloneSZ31, Dianova), and with rabbit anti-aSMA (alpha-Smooth Muscle Actin - EMELCA) for primary incubation and with Alexa Fluor 488 goat anti-rabbit IgG (Dianova) and Alexa Fluor 594 goat anti-rat IgG (Dianova) for secondary incubation, respectively. Primary incubation was performed overnight at 4 °C while secondary incubation was performed for 1 hour at room temperature. p62 staining was performed using rabbit anti p62 (abcam ab91526) for primary incubation (4 °C, overnight), and with anti rabbit 488 (Jackson ImmunoResearch) for secondary incubation (one hour at RT). To visualize the nuclei, tissue sections were counterstained with DAPI.

Statistics
All data were initially tested for normality using the Kolmogorov-Smirnov test. Normally distributed
data were compared using the student’s t-test, not normally distributed data were analyzed using the Mann-Whitney test. Comparisons were always made between two groups. All results are given as mean +/-SEM. A p-value of below 0.05 was considered significant.

Results
In the following paragraphs we will avoid to supply the respective numerical values of the analyzes if possible. All findings are depicted in Figs. 1–7. Before the results will be presented, it needs to be stated that significant adverse events were not observed in any of the experimental groups. Therefore, no animals required euthanization before all analyzes were collected.

Atg5 is constitutively expressed by transfected murine EPCs
After EPC transduction according to the protocol, 73.1 ± 4.6% of the cells showed red fluorescence, indicative for successful Atg5 expression (Fig. 1).

EPCs\textsuperscript{Atg5\textsuperscript{+}} improve post-ischemic serum cystatin C levels
Bilateral renal ischemia resulted in a significant increase in plasma cystatin C at 48 hours. Cystatin C levels remained elevated until week 6. In all ‘48 hours groups’, cell therapy did not substantially modulate concentrations of the metabolite. At 6 weeks however, EPC administration improved persisting kidney dysfunction. Native cells reduced cystatin C, this effect was even more pronounced if transfected cells (EPCs\textsuperscript{Atg5\textsuperscript{+}}) were applied. Together, the findings indicated a reno-protective role of EPCs that express Atg5 in a constitutive manner (Fig. 2).

EPCs and EPCs\textsuperscript{Atg5\textsuperscript{+}} reduce proteinuria in the long-term
At week 6, post-ischemic animals displayed significant proteinuria as compared to untreated controls. Systemic injection of both, native and transfected cells diminished protein excretion with no difference between the two groups (Fig. 3).

Renal fibrosis and Endothelial-to-Mesenchymal Transition (EndoMT) are not significantly reduced in EPCs- or EPCs\textsuperscript{Atg5\textsuperscript{+}}-treated post-ischemic mice
Both, significant matrix deposition and endothelial expression of the mesenchymal marker alpha-Smooth Muscle Actin (aSMA) occurred exclusively in one out of 6 post-ischemic groups: ‘IRI 6 w’. Cell therapy was not reflected by any modulatory effect on neither fibrosis nor EndoMT at all (Figs. 4 and 5).

EPCs\textsuperscript{Atg5\textsuperscript{+}} completely prevent the kidney from peritubular capillary loss
Renal ischemia significantly reduced the peritubular capillary density (PTCD) at 48 hours and 6 weeks. The administration of native (non-transfected) EPCs increased the PTCD at 6 weeks but not earlier.

Transfected cells in contrast completely halted the loss of capillaries at both timepoints (Fig. 6).

**EPCs and EPCs^Atg5+ augment the autophagocytic flux in renal endothelial cells**

As in previous studies we evaluated the autophagocytic flux in endothelial cells by p62 staining [18]. Ischemia alone did not elevate endothelial p62. If native of transfected cells were applied, endothelial p62 increased at 48 hours and 6 weeks (Fig. 7).

**Discussion**

The current study substantially proves reno-protective effects of therapeutically administered EPCs that express Atg5 in a constitutive manner. Firstly, transfected cells improved persisting kidney dysfunction several weeks after ischemia and significantly reduced urinary protein excretion. Secondly, structural endpoints were modulated as well. While interstitial matrix deposition and mesenchymal transdifferentiation of endothelial cells, both occurring at week 6, were not halted, transfected cells completely prevented the loss of peritubular capillaries. The latter has been identified as hallmark of acute ischemia and as risk factor for chronic kidney disease [20]. Administration of transfected cells also increased endothelial p62 abundances, indicative for an increased autophagocytic flux [13, 18].

In the past, we attempted to activate the autophagocytic cascade in EPCs by pharmacological measures exclusively. In total, four substances were evaluated, none of these reliably improved protective effects of the cells in AKI [13, 14]. We assumed that the lack of specificity of such drug-based approaches most likely accounted for the findings reported in previous studies. Cell-based therapies of ischemic and inflammatory diseases have increasingly been investigated in recent years. Most studies have been performed in animals, however, particularly mesenchymal stem cells (MSCs) are currently being evaluated in human diseases including AKI [21, 22]. In parallel, the mechanisms of therapeutic cell actions within the (post)ischemic or inflammatory microenvironment have gained the interest of researchers worldwide. Regarding MSCs and EPCs, two mechanisms have been identified, the release of certain types of vesicles and paracrinic actions, mediated by humoral factors or the so-
called secretome. For more informations regarding EPCs, we would like to refer to the literature [5, 6].

Very recent and yet unpublished data from our laboratory indicated that intact EPCs must home to the postischemic kidney in order to promote AKI protection. In fact, systemically injected microvesicles protected the kidney as well but these effects occurred exclusively under very defined conditions. Previous studies revealed that AKI protection mediated by intact EPCs can be stimulated with several substances such as Angiopoietin-1 and – 2, and the hormone melatonin [4, 8, 9]. In our latest and yet unpublished series of experiments, such stimulatory effects were missing if microvesicles were injected alone. Since pharmacological strategies for AP activation failed so far and we generally strive to augment AKI-protective EPC effects in a persistent manner, genetic modification (herein: Atg5 transfection) became a promising option. To date, only few studies addressed the stimulation of autophagy in EPCs for therapeutic purposes. Zhou and colleagues [23] employed hypoxic preconditioning and found enhanced survival of the cells in a rat model of limb ischemia. Hu et al. [16] described reduced EPC migration and tube formation upon Atg5 inactivation, the authors applied a highly selective strategy (Atg5 gene silencing). Comparable approaches with other cell types such as mesenchymal stem cells (MSCs) have not been reported so far, although autophagy activation in MSCs has been shown to augment cell competence under different experimental conditions [24–26]. The mechanisms by which constitutive Atg5 activation enables the cells to protect the kidney are speculative in nature. Since AP is regarded as self-defensive strategy under certain conditions [11], one may hypothesize that Atg5 transduction increases the lifespan of injected EPCs or their stress-resistance within the post-ischemic microenvironment. However, our approach did not ensure a reliable labelling of EPCs, making any distinct conclusion about longer intra-renal engraftment impossible.

Although selective AP activation appears as promising option for enhancing EPC competence in cell-based AKI therapy, several problems remain. The two most important problems are related to the source of EPCs or other cell-types and the timing of cell administration. These aspects have recently been discussed [22].

In summary, we showed for the first time that constitutive Atg5 expression in therapeutically
administered EPCs can substantially improve AKI protective effects of the cells. The potential consequences for the clinical management of the syndrome need to be defined.

**Conclusion**
Constitutive Atg5 expression in therapeutically administered EPCs substantially improve AKI protective effects of the cells. Cell therapy improved both, excretory kidney function and structural endpoints. The consequences for the clinical management need to be determined.

**Abbreviations**
- AKI
- Acute Kidney Injury
- AP
- Autophagy
- aSMA
- alpha-Smooth Muscle Actin
- Atg5
- Autophagy Related Protein5
- EndoMT
- Endothelial-to-Mesenchymal Transition
- EPCs
- Endothelial Progenitor Cells
- PACs
- Proangiogenic Cells
- PTCD
- Peritubular Capillary Density
- SAHA
- SuberoylAnilide Hydroxamic Acid

**Declarations**
**Ethical approval and consent to participate**
The animal study protocol was in accordance with the guidelines of the German Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. The study did not require consent to participate.

**Consent to publish**
All authors read and approved the final version of the manuscript.

**Availability of data and materials**
Data are available from the authors upon reasonable request (daniel.patschan@mhb-fontane.de).

Competing interests
None.

Funding
The study was supported by the Jackstädt-Stiftung (JS). The JS provided financial support for the whole study. All animals, chemicals, other materials used in animal-based and non-animal-based experiments were funded. The JS did not participate in designing the study nor in data collection or analysis, nor in interpretation of data nor in writing the manuscript.

Authors contributions
DP designed the study, performed analyzes and wrote the article. KS performed all surgical experiments. OR corrected the manuscript and provided financial support. SP analyzed data and corrected the manuscript. GAM provided laboratory space and corrected the manuscript. All authors approved the final version of the article.

Acknowledgements
Not applicable.

References
1. Patschan D, Krupincza K, Patschan S, et al (2006) Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol 291:F176-185.
   https://doi.org/10.1152/ajprenal.00454.2005
2. Patschan D, Patschan S, Gobe GG, et al (2007) Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J Am Soc Nephrol JASN 18:1516–1524.
   https://doi.org/10.1681/ASN.2006070759
3. Patschan D, Patschan S, Wessels JT, et al (2010) Epac-1 activator 8-O-cAMP augments renoprotective effects of syngeneic [corrected] murine EPCs in acute ischemic kidney injury. Am J Physiol Renal Physiol 298:F78-85.
   https://doi.org/10.1152/ajprenal.00485.2009
4. Patschan D, Hildebrandt A, Rinneburger J, et al (2012) The hormone melatonin
stimulates renoprotective effects of “early outgrowth” endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol 302:F1305-1312.
https://doi.org/10.1152/ajprenal.00445.2011

5. Cantaluppi V, Gatti S, Medica D, et al (2012) Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 82:412-427.
https://doi.org/10.1038/ki.2012.105

6. Basile DP, Collett JA, Yoder MC (2017) Endothelial colony-forming cells and pro-angiogenic cells: clarifying definitions and their potential role in mitigating acute kidney injury. Acta Physiol Oxf Engl. https://doi.org/10.1111/apha.12914

7. Richardson MR, Yoder MC (2011) Endothelial progenitor cells: quo vadis? J Mol Cell Cardiol 50:266-272. https://doi.org/10.1016/j.yjmcc.2010.07.009

8. Patschan D, Backhaus R, Elle HJ, et al (2013) Angiopoietin-2 modulates eEOC-mediated renoprotection in AKI in a dose-dependent manner. J Nephrol 0.
https://doi.org/10.5301/jn.5000255

9. Patschan D, Rinneburger J, Idrizi N, et al (2013) Angiopoietin-1 treated early endothelial outgrowth cells (eEOCs) are activated in vitro and reduce renal damage in murine acute ischemic kidney injury (iAKI). BMC Nephrol 14:227.
https://doi.org/10.1186/1471-2369-14-227

10. Patschan D, Schwarze K, Lange A, et al (2013) Bone morphogenetic protein-5 and early endothelial outgrowth cells (eEOCs) in acute ischemic kidney injury (AKI) and 5/6-chronic kidney disease. Am J Physiol Renal Physiol 305:F314-322.
https://doi.org/10.1152/ajprenal.00677.2012

11. Klionsky DJ, Abdelmohsen K, Abe A, et al (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222.
12. Jin M, Klionsky DJ (2014) Regulation of autophagy: Modulation of the size and number of autophagosomes. FEBS Lett 588:2457–2463. https://doi.org/10.1016/j.febslet.2014.06.015

13. Patschan D, Schwarze K, Henze E, et al (2015) Endothelial autophagy and Endothelial-to-Mesenchymal Transition (EndoMT) in eEPC treatment of ischemic AKI. J Nephrol. https://doi.org/10.1007/s40620-015-0222-0

14. Schwarze K, Kribben A, Ritter O, et al (2018) Autophagy activation in circulating proangiogenic cells aggravates AKI in type I diabetes mellitus. Am J Physiol Renal Physiol 315:F1139–F1148. https://doi.org/10.1152/ajprenal.00502.2017

15. Torisu T, Torisu K, Lee IH, et al (2013) Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor. Nat Med 19:1281–1287. https://doi.org/10.1038/nm.3288

16. Hu N, Kong L-S, Chen H, et al (2015) Autophagy protein 5 enhances the function of rat EPCs and promotes EPCs homing and thrombus recanalization via activating AKT. Thromb Res 136:642–651. https://doi.org/10.1016/j.thromres.2015.06.038

17. Lenoir O, Jasiek M, Hénique C, et al (2015) Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis. Autophagy 11:1130–1145. https://doi.org/10.1080/15548627.2015.1049799

18. Patschan D, Schwarze K, Henze E, et al (2014) eEOC-mediated modulation of endothelial autophagy, senescence, and EnMT in murine diabetic nephropathy. Am J Physiol Renal Physiol 307:F686-694. https://doi.org/10.1152/ajprenal.00650.2013

19. Patschan D, Schwarze K, Henze E, et al (2016) The endothelial-to-mesenchymal transition and endothelial cilia in EPC-mediated postischemic kidney protection. Am J Physiol Renal Physiol 310:F679–F687. https://doi.org/10.1152/ajprenal.00306.2015
20. Basile DP (2007) The endothelial cell in ischemic acute kidney injury: implications for acute and chronic function. Kidney Int 72:151–156. https://doi.org/10.1038/sj.ki.5002312

21. Dellepiane S, Medica D, Quercia AD, Cantaluppi V (2017) The exciting “bench to bedside” journey of cell therapies for acute kidney injury and renal transplantation. J Nephrol 30:319–336. https://doi.org/10.1007/s40620-017-0384-z

22. Patschan D, Buschmann I, Ritter O, Kribben A (2018) Cell-Based Therapies in Acute Kidney Injury (AKI). Kidney Blood Press Res 43:673–681. https://doi.org/10.1159/000489624

23. Zhou P, Tan Y-Z, Wang H-J, Wang G-D (2017) Hypoxic preconditioning-induced autophagy enhances survival of engrafted endothelial progenitor cells in ischaemic limb. J Cell Mol Med 21:2452–2464. https://doi.org/10.1111/jcmm.13167

24. Wang HY, Li C, Liu WH, et al (2019) Autophagy inhibition via Becn1 downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis. J Cell Physiol. https://doi.org/10.1002/jcp.29176

25. Liang D, Han D, Fan W, et al (2016) Therapeutic efficacy of apelin on transplanted mesenchymal stem cells in hindlimb ischemic mice via regulation of autophagy. Sci Rep 6:21914. https://doi.org/10.1038/srep21914

26. Dang S, Xu H, Xu C, et al (2014) Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis. Autophagy 10:1301–1315. https://doi.org/10.4161/auto.28771

Figures
evaluation of the Atg5 transfection rate. View fields analysis revealed that 73.1 ±4.6% of the cells showed red fluorescence, indicative for successful transfection. A: red signal indicates Atg5 expression; B: DAPI staining (nuclei); C: merge (magnifications in A - C: ×40; Data in D as mean +/- SEM).
serum cystatin C levels in all control and experimental groups. Bilateral renal ischemia (IRI - Ischemia Reperfusion Injury) induced significant excretory kidney dysfunction as indicated by elevated serum cystatin C. While cell therapy failed to improve kidney function in all ’48 hours´ groups, kidney function improved at week 6, particularly after the administration of transfected cells (Data as mean +/- SEM, *: p<0.05).
proteinuria in all ‘6 weeks´ groups. Protein excretion was significantly elevated after ischemia and decreased as a results of cell thera-py. Anti-proteinuric effects were observed in the presence of both, native and transfected cells (Data as mean +/- SEM, *: p-value between ‘Control 6 w´ and ‘IRI 6 w´ <0.05; #: p-value between ‘IRI 6 w´ and either ‘IRI+EPCs 6w´ or ‘IRI+EPCsAtg5 6w´ <0.05).
Figure 4

Interstitial fibrosis, evaluated after masson trichrome staining. Significant matrix deposition occurred exclusively in one group: ‘IRI 6 w’. All other groups did not differ between each other or in comparison to the control groups. The white oval in C surrounds an area of higher matrix density (magnifications in A - C: ×40; Data in D as mean +/- SEM).
Figure 5

Endothelial-to-mesenchymal transition. Comparably to the fibrosis patterns, only one group (´IRI 6 w´) showed different aSMA abundances in CD31+ cells. EPC treatment, either performed with native or transfected cells, did not modulate endothelial aSMA in a significant manner. Image D magnifies the surrounded (white rectangular) area in C. The white circle in D surrounds the borderzone between media (musculature - green) and intima, predominately represented by the endothelial layer (red). The yellow indicates aSMA expression by CD31+ cells (magnifications in B and C: ×40, in D ~×160; Data in A as mean +/- SEM; *: p-value between ´Control 6 w´ and ´IRI 6 w´ <0.05).
peritubular capillary density (PTCD), evaluated after CD31 staining. IRI resulted in decreased PTCD at 48 hours and 6 weeks, respectively. Native (non-transfected) EPCs increased the PTCD at 6 weeks but not earlier. Transfected cells however prevented the loss of capillaries completely (48 hours and 6 weeks) (magnifications in B-D ×40; Data in A as mean +/- SEM; #: p-values between different groups of the ‘48 hours cohort’ <0.05 – the bracketed lines indicate comparisons between two groups; #: p-values between different groups of the ‘6 weeks cohort’ <0.05 – the bracketed lines indicate respective comparisons).
Figure 7

analysis of the p62 expression in CD31+ (endothelial) cells. As in previous reports by our group, the autophagocytic flux was evaluated by p62 staining. IRI alone did not elevate endothelial p62. If native of transfected cells were applied however, endothelial p62 increased at both, 48 hours and 6 weeks. Images B-E show kidney sections from one Control group (48 hours), F-I display sections from an ani-m-al that received transfected EPCs (48 hours). B+F: staining of p62 exclusively; C+G: staining of CD31 exclusively; D+H: merge; E+I: magnifications of D and H. (magnifications in B-D and in F-H ×40; in E and I ∼ ×60; green: p62; red: CD31; blue: nuclei; Data in A as mean +/- SEM; *: p-values between certain groups of the ‘48 hours cohort´ <0.05 – the bracketed lines indicate comparisons between two groups; #: p-values between different groups of the ‘6 weeks cohort´ <0.05 – the bracketed lines indicate respective comparisons).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

NC3Rs ARRIVE Guidelines Checklist (fillable).pdf